FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileAmplify Weight Loss Drug & Treatment ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
THNR
Amplify Weight Loss Drug & Treatment ETF ETF AnalysisComprehensive ETF analysis for Amplify Weight Loss Drug & Treatment ETF (THNR) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisTHNR
THNR
Amplify Weight Loss Drug & Treatment ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
THNR
  1. Home
  2. Screener
  3. Amplify Weight Loss Drug & Treatment ETFTHNRETF
Amplify Weight Loss Drug & Treatment ETF Logo

Amplify Weight Loss Drug & Treatment ETF

ETF
🇺🇸THNR•AMEX•Equity

Your view on THNR

Amplify Weight Loss Drug & Treatment ETF Logo

Amplify Weight Loss Drug & Treatment ETF

ETFAmplify
🇺🇸THNR•AMEX•Equity
AUM (USD)$5.22M
Expense Ratio0.59%
Yield (TTM)1.65%
Holdings20

Sentiment

—

AUM (USD)

$5.22M

Expense Ratio

0.59%

Yield (TTM)

1.65%

Holdings

20

Sentiment

—
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

Amplify Weight Loss Drug & Treatment ETF (THNR) is an Equity fund from Amplify, listed since 2024, with $5.2M in assets under management, a 0.59% expense ratio and a NAV of $26.08 USD.

Overview for Amplify Weight Loss Drug & Treatment ETF

Fund Type
ETF
Fund Issuer
Amplify
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
May 21, 2024
Domicile
US
Website
amplifyetfs.com/thnr
Fund Type
ETF
Fund Issuer
Amplify
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
May 21, 2024
Domicile
US
Website
amplifyetfs.com/thnr
Fund Type
ETF
Fund Issuer
Amplify
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
May 21, 2024
Domicile
US
Website
amplifyetfs.com/thnr

About this fund

THNR provides access to global companies expected to economically benefit from weight loss drug development. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

0.59%

Yield (TTM)

1.65%

AUM

$5.22M

Fund Details

NAV$26.08 USD
Holdings20
Average Volume1.2K
Inception DateMay 21, 2024
Asset ClassEquity
Fund IssuerAmplify
DomicileUS
ISINUS0321085328
CUSIP032108532
NAV CurrencyUSD

Expense Ratio

0.59%

Dividend Yield (TTM)

1.65%

Assets Under Management

$5.22M

NAV

$26.08 USD

Holdings

20

Average Volume

1.2K

Inception Date

May 21, 2024

Asset Class

Equity

Fund Issuer

Amplify

Domicile

US

ISIN

US0321085328

CUSIP

032108532

NAV Currency

USD

Expense Ratio

0.59%

Dividend Yield (TTM)

1.65%

Assets Under Management

$5.22M

NAV

$26.08 USD

Holdings

20

Average Volume

1.2K

Inception Date

May 21, 2024

Asset Class

Equity

Fund Issuer

Amplify

Domicile

US

ISIN

US0321085328

CUSIP

032108532

NAV Currency

USD

Distributions · last 12 months

Irregular · 1 payment

Ex-datePaidAmount
Dec 30, 2025Dec 31, 2025$0.4132
Total, 12 months$0.41 a share

Dividend yield (TTM) 1.65% = $0.41 paid per share in the 12 months to Nov 20, 2026 ÷ the $25.01 price. Past distributions; future payments can differ.

Data last updated: Nov 17, 2026, 08:11 AM

Sectors

How the fund's assets are split across sectors.

1 sectors
  • 1Healthcare
    100.0%

Top sector

Healthcare

Top weight

100.0%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

22 positions
1LLYEli Lilly & Co
12.07%
2NVONovo Nordisk A/S
8.77%
3REGNRegeneron Pharmaceuticals Inc
6.23%
4AMGNAmgen Inc
6.06%
5GILDGilead Sciences Inc
5.92%
6ROP.SWRoche Holding AG
5.86%
7AZNAstraZeneca PLC
5.85%
8ABBVAbbVie Inc
5.70%
94519.TChugai Pharmaceutical Co Ltd
5.42%
10PFEPfizer Inc
5.30%
11MRKMerck & Co Inc
4.83%
121093.HKCSPC Pharmaceutical Group Ltd
4.59%
131801.HKInnovent Biologics Inc
4.46%
14VKTXViking Therapeutics Inc
4.13%
15128940.KSHanmi Pharm Co Ltd
3.13%

Concentration

Total Holdings22
Top 10 Weight67.17%
Top HoldingLLY
Top Weight12.07%
1LLYEli Lilly & Co
12.07%
2NVONovo Nordisk A/S
8.77%
3REGNRegeneron Pharmaceuticals Inc
6.23%
4AMGNAmgen Inc
6.06%
5GILDGilead Sciences Inc
5.92%
6ROP.SWRoche Holding AG
5.86%
7AZNAstraZeneca PLC
5.85%
8ABBVAbbVie Inc
5.70%
94519.TChugai Pharmaceutical Co Ltd
5.42%
10PFEPfizer Inc
5.30%
11MRKMerck & Co Inc
4.83%
121093.HKCSPC Pharmaceutical Group Ltd
4.59%
131801.HKInnovent Biologics Inc
4.46%
14VKTXViking Therapeutics Inc
4.13%
15128940.KSHanmi Pharm Co Ltd
3.13%

Total Holdings

22

Top 10 Weight

67.17%

Top Holding

LLY

Top Weight

12.07%

1LLYEli Lilly & Co
12.07%$604.3K
2NVONovo Nordisk A/S
8.77%$439.2K
3REGNRegeneron Pharmaceuticals Inc
6.23%$312.0K
4AMGNAmgen Inc
6.06%$303.6K
5GILDGilead Sciences Inc
5.92%$296.7K
6ROP.SWRoche Holding AG
5.86%$293.3K
7AZNAstraZeneca PLC
5.85%$292.8K
8ABBVAbbVie Inc
5.70%$285.4K
94519.TChugai Pharmaceutical Co Ltd
5.42%$271.4K
10PFEPfizer Inc
5.30%$265.3K
11MRKMerck & Co Inc
4.83%$242.1K
121093.HKCSPC Pharmaceutical Group Ltd
4.59%$230.0K
131801.HKInnovent Biologics Inc
4.46%$223.5K
14VKTXViking Therapeutics Inc
4.13%$207.0K
15128940.KSHanmi Pharm Co Ltd
3.13%$156.9K

Total Holdings

22

Top 10 Weight

67.17%

Top Holding

LLY

Top Weight

12.07%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on17 funds
FundAsset classExpense ratioAssetsHoldings
THNRAmplify Weight Loss Drug & Treatment ETFThis fundEquity0.59%$5M20

Comparable funds

  • CDIGCity Different Investments Global Equity ETFEquity0.75%$55M0
  • DUKXOcean Park International ETFEquity5.28%$4M0
  • EAFGPacer Developed Markets Cash Cows Growth Leaders ETFEquity0.65%$2M112
  • GENDGenter Capital Dividend Income ETFEquity0.38%$7M33
  • IONProShares - S&P Global Core Battery Metals ETFEquity0.58%$8M54

More Amplify ETFs

  • AWAYAmplify Travel Tech ETFEquity0.75%$24M28
  • BAGYAmplify Bitcoin Max Income Covered Call ETFAlternatives0.65%$8M3
  • BATTAmplify Lithium & Battery Technology ETFEquity0.59%$90M52
  • BDRYBreakwave Dry Bulk Shipping ETFEquity3.50%$29M15
  • BLOKAmplify Blockchain Technology ETFEquity0.70%$817M48
  • BWETBreakwave Tanker Shipping ETFEquity3.50%$70M10
  • CNBSAmplify Seymour Cannabis ETFEquity1.09%$64M33
  • COWSAmplify Cash Flow Dividend Leaders ETFEquity0.39%$48M40
  • DIVOAmplify CWP Enhanced Dividend Income ETFEquity0.56%$7.9B38
  • DRVRAmplify S&P 500 Dividend Drivers ETFEquity0.39%$795,95248
  • ETHOAmplify Etho Climate Leadership U.S. ETFEquity0.45%$197M283
  • GAMRAmplify Video Game Leaders ETFEquity0.59%$39M23
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.

News

Latest Market News

News

Latest Market News